Actively Recruiting
Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors
Led by VelaVigo Bio Inc · Updated on 2026-04-22
255
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a multicenter, open-label, multi-dose, first-in-human (FIH) Phase I/IIa study to determine the safety and tolerability of VBC103, as well as the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D), PK and further evaluate its efficacy.
CONDITIONS
Official Title
Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willingness and ability to sign informed consent before starting study procedures
- Histologically or cytologically confirmed unresectable advanced or metastatic solid tumor that has progressed after or is intolerant to standard therapy, or lacks standard treatment options
- At least one measurable tumor lesion according to RECIST v1.1
- Adults aged 18 years or older
- ECOG performance status of 0 or 1
- Left ventricular ejection fraction (LVEF) of 50% or higher measured by ECHO or MUGA within 28 days before enrollment
- Life expectancy longer than 12 weeks
- Availability of archived tumor tissue samples or willingness to undergo biopsy sampling
You will not qualify if you...
- Any unresolved grade 2 or higher toxicity from previous anticancer therapy
- Known active keratitis or corneal ulcer
- History or current presence of interstitial lung disease or suspected interstitial lung disease based on imaging
- History of significant pulmonary diseases within 3 months prior to investigational product start, including pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, or other serious lung impairment
- Autoimmune, connective tissue, or inflammatory diseases affecting the lungs such as rheumatoid arthritis, Sjögren's syndrome, sarcoidosis
- Prior complete lung resection (pneumonectomy)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 201209
Actively Recruiting
Research Team
J
Jian Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here